A Non Cancer-Related Survival Benefit Is Associated With Partial Nephrectomy
|
|
- Allyson Berry
- 5 years ago
- Views:
Transcription
1 EUROPEAN UROLOGY 61 (2012) available at journal homepage: Platinum Priority Kidney Cancer Editorial by Alexander Kutikov, Marc C. Smaldone, Brian L. Egleston and Robert G. Uzzo on pp of this issue A Non Cancer-Related Survival Benefit Is Associated With Partial Nephrectomy Maxine Sun a, *, Quoc-Dien Trinh a,b, Marco Bianchi a,c, Jens Hansen a,d, Nawar Hanna a, Firas Abdollah c, Shahrokh F. Shariat e, Alberto Briganti c, Francesco Montorsi c, Paul Perrotte f, Pierre I. Karakiewicz a,f a Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; b Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA; c Department of Urology, Vita Salute San Raffaele University, Milan, Italy; d Martini-Klinic, Prostate Cancer Center Hamburg- Eppendorf, Hamburg, Germany; e Department of Urology, Weill Medical College, Cornell University, New York, NY, USA; f Department of Urology, University of Montreal Health Center, Montreal, Canada Article info Article history: Accepted November 24, 2011 Published online ahead of print on December 2, 2011 Keywords: Other-cause mortality Partial nephrectomy Radical nephrectomy Competing-risks Survival Please visit europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically. Abstract Background: Partial nephrectomy (PN) may better protect against other-cause mortality (OCM) when compared with radical nephrectomy (RN) in patients with localized renal cell carcinoma (RCC). Objective: Test the effect of treatment type on OCM. Design, setting, and participants: Using the Surveillance Epidemiology and End Results Medicare-linked database, 4956 RN patients (82%) and 1068 PN patients (18%) with T1a RCC were identified ( ). Measurements: To adjust for inherent differences between treatment types, we relied on propensity-matched analyses. One-to-one matching was performed according to age, sex, race, baseline Charlson comorbidity index (CCI), baseline diagnosis of hypercalcemia and hyperlipidemia, socioeconomic status (SES), population density, tumor size, and year of surgery. The 2- and 5-yr OCM rates were computed using cumulative incidence. Univariable and multivariable competing-risks regression analyses for prediction of OCM were performed according to treatment type. Adjustment was made for cancerspecific mortality (CSM), patient age, CCI, sex, race, SES, tumor grade, and year of surgery. Results and limitations: Following propensity-based matching, 1068 RN patients were matched with 1068 PN patients. The 2- and 5-yr OCM rates after nephrectomy were 5.0% and 16.0% for PN versus 6.9% and 18.1% for RN, respectively. In the postpropensity multivariable analyses, patients who underwent PN were significantly less likely to die of OCM compared with their RN-treated counterparts (hazard ratio [HR]: 0.83; 95% confidence interval, ; p = 0.04). Increasing age (HR: 1.08, p < 0.001), higher CCI (HR: 1.14, p < 0.001), female gender (HR: 0.79, p = 0.02), baseline hypercalcemia (HR: 2.05, p = 0.03), baseline hyperlipidemia (HR: 0.73, p = 0.003), and year of surgery (HR: 0.95, p = 0.003) were independent predictors of OCM. Conclusions: Compared with PN-treated patients, RN-treated patients are more likely to die of OCM after surgery, even after adjusting for CSM, as well as baseline CCI. Consequently, PN should be offered whenever technically feasible. Crown Copyright # 2011 Published by Elsevier B.V. on behalf of European Association of Urology. All rights reserved. * Corresponding author. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, 264 Boul. René-Lévesque East, Suite 228, Montreal QC, Canada, H2X 1P1. Tel ext ; Fax: address: mcw.sun@umontreal.ca (M. Sun) /$ see back matter Crown Copyright # 2011 Published by Elsevier B.V. on behalf of European Association of Urology. All rights reserved. doi: /j.eururo
2 726 EUROPEAN UROLOGY 61 (2012) Introduction Because of the increased incidence of localized renal cell carcinoma (RCC) and downward stage migration [1,2], utilization rates of partial nephrectomy (PN) have risen significantly [3,4]. Compared with radical nephrectomy (RN), PN has been shown to provide improved renal function [5],a lower risk of cardiovascular events [6], and improved survival [6,7]. Despite the established benefits, utilization of PN remains low in the community setting (45% in 2006) [8]. In contrast, RN remains the most common procedure performed for patients with small renal masses worldwide. Its widespread use may be detrimental in patients with multiple baseline conditions and competing causes of mortality, given that only a small minority of patients with localized RCC will die of cancer-specific mortality (CSM). Previous studies that have reported improved mortality in PN-treated patients compared with RN-treated patients in the community setting failed to account for baseline comorbidities [7], as well as CSM events [6,7]. Consequently, we sought to compare the effect of treatment type namely, PN compared with RN on other-cause mortality (OCM), using a larger and more contemporary population-based cohort and with the consideration of baseline conditions and means of competing-risks mortality, which represents CSM in this context. The current study represents an update of T1a RCC patients treated with PN or RN between 1988 and 2005, extracted from the Surveillance Epidemiology and End Results (SEER) Medicare-linked database. 2. Patients and methods Terminology coding system, fourth edition (CPT 4), within 6 mo of primary diagnosis of RCC. Patients who underwent RN were identified using ICD 9 procedure code 55.5x or CPT 4 codes 50220, 50225, 50230, 50545, and Patients who underwent PN were identified by the presence of ICD 9 procedure code 55.4 or CPT 4 codes 50240, 50280, 50290, and Patients who had a claim for PN followed by a claim for RN within 30 d were defined as RN and vice versa Patient and sociodemographic characteristics Patient age at diagnosis, residence (rural, urban), marital status (married, single, unmarried, unknown), and year of surgery were obtained from the Medicare file. Information on sex and race (white, black, other) was obtained using the SEER demographic data file. Subject comorbidity was quantified using the Klabunde modification [10] of the Charlson comorbidity index (CCI) [11], which gives a weighted score based on diagnosis in which a higher score indicates a subject with a greater burden of comorbid conditions (0, 1, 2, 3). Additional comorbidities associated with RCC outcomes were considered: hypercalcemia (ICD 9: ) and hyperlipidemia (ICD 9: 272.4, 272.0, 272.2) [12]. Socioeconomic status (SES) was defined according to three countyattribute variables: education level as the percentage of persons who did not complete high school, poverty as the percentage of persons living below the poverty line at the time, and the median family income. These county-attribute variables were measured using the 2000 census documentation files available at cen2000.html. We created a composite variable of SES using the three variables previously mentioned based on the previous methodology [13]. First, we recoded the variables individually to ensure that low values represent low SES, and vice versa. Second, we transformed all values into standardized scores. Third, we computed the sum of these scores and categorized the total scores into two groups according to the median, which resulted in our low and high SES Data source 2.5. Tumor characteristics The current study relied on the SEER Medicare-linked database. The SEER regions represented approximately 14% of the US population prior to the year 2000 and 26% of the US population thereafter [9]. The Medicarelinked database is 98% complete for case ascertainment. The database encompasses approximately 97% of persons 65 yr in the United Sates. Linkage to the SEER database is complete for roughly 93% of the patients Study population Patients with a primary diagnosis of nonmetastatic T1a RCC (C64.0) between 1988 and 2005 were analyzed. Moreover, patients were included only if they had both Medicare Part A and Part B claims available 12 mo before the first recorded diagnosis and 6 mo after diagnosis and if they were not enrolled in a health maintenance organization throughout the duration of the study period. This step allows computation of a noncancer comorbidity score and relevant treatment information following diagnosis. RCC diagnoses based on autopsy were removed from the study, as were RCC diagnoses whose original or current reason for Medicare entitlement was listed as disability or Medicare status code including disability. These exclusion criteria resulted in an overall study population of 6024 patients Treatment type Treatmenttype was identified by searching Part A andpart B Medicare files and the outpatient claims file using the codes of the International Classification of Diseases, ninth revision (ICD 9), or the Current Procedural No patients had any known presence of nodal metastases or distant metastases at surgery. Tumor size was assigned using the variables named e10sz1 for patients diagnosed between 1991 and 2003 and cstum1 for patients diagnosed between 2004 and Statistical analyses Frequencies and proportions were assessed for categorical variables, while means, medians, andinterquartile rangeswere computedforcontinuously coded variables. The chi-square test and independent Mann-Whitney test were used to test the statistical significance of proportions and medians, respectively. First, because of inherent differences between patients undergoing PN and RN in terms of baseline patient and hospital characteristics, we used 1:1 nearest-neighbor propensity-score matched analyses to adjust for these differences. The use of the propensity score method eliminates the customary bias associated with the conventional multivariable modeling approach [14,15]. Propensity scores were computed by modeling a logistic regression with the dependent variable as the odds of undergoing a PN and the independent variables as patient age, sex, race, baseline CCI, year of surgery, marital status, SES, population density, baseline hypercalcemia, baseline hyperlipidemia, and tumor size. Subsequently, covariate balance between the matched groups was examined. Second, univariable and multivariable competing-risks regression analyses for prediction of OCM were performed to assess the effect of treatment type. Covariates comprised CSM, patient age, baseline CCI, sex, race, SES, marital status, population density, tumor size, baseline
3 EUROPEAN UROLOGY 61 (2012) hypercalcemia, baseline hyperlipidemia, Fuhrman grade, and year of surgery. All tests were two-sided, with a statistical significance set at p < Analyses were conducted using the statistical package for R v (R Foundation for Statistical Computing, Vienna, Austria). 3. Results Of 6024 T1a RCC patients, 1068 (18%) and 4956 (82%) were treated with PN and RN, respectively (Table 1). Prior to propensity-based adjustment, PN-treated patients were slightly younger than RN-treated patients (median: 72 yr compared with 74 yr, respectively; p < 0.001) and were more likely to have multiple baseline comorbidities than RN-treated patients (CCI 3: 33% compared with 30%, respectively; p < 0.001). Moreover, PN-treated patients compared with RN-treated patients were more likely to be male (59% compared with 52%, respectively; p < 0.001), to be married (66% compared with 61%, respectively; p < 0.001), to reside in a county described as high SES (51% compared with 37%, respectively; p < 0.001), and to harbor smaller tumors (median: 2.5 cm compared with 3.0 cm, respectively; p < 0.001). Relying on propensity-score matched analyses, 1068 RN patients were matched to another 1068 PN patients (Table 1). Baseline patient and sociodemographic differences, as well as tumor characteristic differences, between PN and RN were now comparable between the two groups, as demonstrated by standardized mean differences of <10%, which signifies a high degree of similarity in the distribution of both populations. Within the matched cohort, the 2- and 5-yr OCM rates were 5.0% and 16.0% for PN, compared with 6.9% and 18.1% for RN, respectively (hazard ratio [HR]: 0.85; 95% confidence interval [CI], ; p = 0.096). In multivariable analyses that accounted for other covariates, including CSM Table 1 Baseline descriptive characteristics of 6024 T1a renal cell carcinoma patients treated with partial or radical nephrectomy, * Variables Overall Prepropensity Postpropensity PN RN Std. mean diff. PN RN Std. mean diff. Patients, no. (%) 6024 (100) 1068 (17.7) 4956 (82.3) 1068 (50.0) 1068 (50.0) Age, yr Mean (median) 74 (73) 72 (72) 74 (74) 72 (72) 72 (71) Interquartile range Sex Male, no. (%) 3197 (53.1) 629 (58.9) 2568 (51.8) 629 (58.9) 643 (60.2) Female, no. (%) 2827 (46.9) 439 (41.1) 2388 (48.2) 439 (41.1) 425 (39.8) Race White, no. (%) 5164 (85.7) 901 (84.4) 4263 (86.0) 901 (84.4) 912 (85.4) Black, no. (%) 441 (7.3) 95 (8.9) 346 (7.0) 95 (8.9) 79 (7.4) Other, no. (%) 419 (7.0) 72 (6.7) 347 (7.0) 72 (6.7) 77 (7.2) Marital status Married, no. (%) 3721 (61.8) 703 (65.8) 3018 (60.9) 703 (65.8) 716 (67.0) Single, no. (%) 388 (6.4) 70 (6.6) 318 (6.4) 70 (6.6) 66 (6.2) Previously married, no. (%) 1734 (28.8) 259 (24.3) 1475 (29.8) 259 (24.3) 261 (24.4) Unknown, no. (%) 181 (3.0) 36 (3.4) 145 (2.9) 36 (3.4) 25 (2.3) Socioeconomic status High, no. (%) 2397 (39.8) 543 (50.8) 1854 (37.4) 543 (50.8) 511 (47.8) Low, no. (%) 2388 (39.6) 457 (42.8) 1931 (39.0) 457 (42.8) 481 (45.0) Unknown, no. (%) 1239 (20.6) 68 (6.4) 1171 (23.6) 68 (6.4) 76 (7.1) Population density Urban, no. (%) 5512 (91.5) 989 (92.6) 4523 (91.3) 989 (92.6) 981 (91.9) Rural, no. (%) 512 (8.5) 79 (7.4) 433 (8.7) 79 (7.4) 87 (8.1) CCI , no. (%) 2204 (36.6) 366 (34.3) 1838 (37.1) 366 (34.3) 373 (34.9) 1, no. (%) 991 (16.5) 184 (17.2) 807 (16.3) 184 (17.2) 189 (17.7) 2, no. (%) 1016 (16.9) 169 (15.8) 847 (17.1) 169 (15.8) 174 (16.3) 3, no. (%) 1813 (30.1) 349 (32.7) 1464 (29.5) 349 (32.7) 332 (31.1) Baseline hypercalcemia, no. (%) 100 (1.7) 22 (2.1) 78 (1.6) (2.1) 23 (2.2) Baseline hyperlipidemia, no. (%) 3532 (58.6) 755 (70.7) 2777 (56.0) (70.7) 743 (69.6) Tumor size, cm Mean (median) 2.9 (3.0) 2.6 (2.5) 3.0 (3.0) 2.6 (2.5) 2.6 (2.5) Interquartile range Year of surgery , no. (%) 1626 (27.0) 109 (10.2) 1517 (30.6) 109 (10.2) 101 (9.5) , no. (%) 1816 (30.1) 270 (25.3) 1546 (31.2) 270 (25.3) 277 (25.9) , no. (%) 1316 (21.8) 303 (28.4) 1013 (20.4) 303 (28.4) 309 (28.9) , no. (%) 1266 (21.0) 386 (36.1) 880 (17.8) 386 (36.1) 381 (35.7) PN = partial nephrectomy; RN = radical nephrectomy; std. mean diff. = standardized mean differences; CCI = Charlson comorbidity index. * Surveillance Epidemiology and End Results Medicare-linked database.
4 728 EUROPEAN UROLOGY 61 (2012) Table 2 Postpropensity univariable and multivariable competing-risks regression analyses for prediction of other-cause mortality among 2136 T1a renal cell carcinoma patients, * Variables Univariable Multivariable HR (95% CI) p value HR (95% CI) p value Treatment type Radical nephrectomy Ref Ref Partial nephrectomy 0.85 ( ) ( ) 0.04 Age 1.08 ( ) < ( ) <0.001 CCI 1.14 ( ) < ( ) <0.001 Sex Male Ref Ref Female 0.85 ( ) ( ) 0.02 Race White Ref Ref Black 1.46 ( ) ( ) 0.07 Other 0.75 ( ) ( ) 0.2 Socioeconomic status High Ref Ref Low 1.07 ( ) ( ) 0.2 Unknown 1.41 ( ) ( ) 0.7 Marital status Married Ref Ref Single 1.34 ( ) ( ) 0.2 Previously married 1.13 ( ) ( ) 0.5 Unknown 1.21 ( ) ( ) 0.5 Population density Urban Ref Ref Rural 0.97 ( ) ( ) 1.0 Tumor size 1.00 ( ) ( ) 0.6 Baseline hypercalcemia 1.64 ( ) ( ) 0.03 Baseline hyperlipidemia 0.76 ( ) ( ) Fuhrman grade I II Ref Ref III 1.03 ( ) ( ) 0.4 IV 1.30 ( ) ( ) 0.4 Unknown 1.02 ( ) ( ) 0.9 Year of surgery 0.96 ( ) < ( ) HR = hazard ratio; CI = confidence interval; CCI = Charlson comorbidity index; Ref. = referent category. * Surveillance Epidemiology and End Results Medicare-linked database. (Table 2), PN was associated with a decreased risk of OCM compared with RN (HR: 0.83; 95% CI, ; p = 0.04). Of note, female gender (HR: 0.79; 95% CI, ), baseline hyperlipidemia (HR: 0.73; 95% CI, ), and more contemporary treated patients (HR: 0.95; 95% CI, ) were also independently associated with a lower risk of OCM. 4. Discussion In the last two decades, PN has become the gold standard for treatment of T1a RCC, even in the context of a normal contralateral kidney [16]. Existing data show equal CSM rates between PN and RN, as well as superiority of preservation of renal function, prevention of chronic kidney disease, improved long-term cardiac morbidity, and improved overall survival [5 7,17,18]. Given the established benefits, PN should be performed whenever technically feasible. Unfortunately, the adoption of PN has been predominantly concentrated at select hospitals and has been substantially less gradual in the community setting than in centers of excellence [19,20]. Moreover, given the increased popularity of laparoscopy in recent years [21], laparoscopic RN may have further overshadowed PN. Given the equivalence of oncologic outcomes, treatmentinduced chronic kidney disease, and related cardiovascular events, RN-treated patients may be at higher risk for OCM compared with PN-treated patients. Two previous studies have reported convincing data on this matter. Huang et al. [6], relying on the SEER Medicare-linked database, demonstrated that RN was associated with a greater risk of overall mortality compared with PN (HR: 1.38; p < 0.01; n = 2547). Similarly, Zini et al. [7], using the SEER limited data, demonstrated a 1.23-fold higher risk of overall mortality for RN compared with PN ( p = 0.001). However, previous studies either failed to account for inherent patient and sociodemographic differences between PN and RN individuals or the consideration of baseline conditions, or else they did not account for the effect of CSM, looking at overall survival only. In the current study, we sought to overcome all the aforementioned caveats by examining and comparing OCM rates between PN and RN patients relying on propensity-based matching within a competing-risks regression analysis. Baseline conditions, defined as CCI, as well as hypercalcemia and hyperlipidemia, were also considered. The first principal finding relates to recorded patient and sociodemographic differences between PN- and RN-treated
5 EUROPEAN UROLOGY 61 (2012) individuals. Similar to previous studies, PN-treated patients were more likely to be male, white, married, and residing in a county of high SES. Moreover, use of PN decreased with increasing age and increasing tumor size. It is noteworthy that PN patients were more likely to harbor multiple baseline comorbidities and had higher rates of hypercalcemia and hyperlipidemia at RCC diagnosis. These observations are consistent with the underlying renal insufficiency that exists in many PN candidates. Second, our study was able to identify a protective effect of PN on OCM compared with RN only in multivariable analyses. In univariable analyses, in contrast, treatment type by itself was not associated with a lower risk of OCM. These findings may reflect a careful selection of PN candidates and further highlight the importance of individualized treatment decision making. For example, only a minority of patients diagnosed with small renal masses will actually die of CSM. In that regard, surgical intervention can only be considered appropriate if it can be curative and when the cancer is likely to reduce the life expectancy of the individual. In other cases, active treatment may prove to be a futile attempt, especially in some patients with very advanced age and a high prevalence of comorbidities. Authors recently showed that neither PN nor RN was associated with a survival benefit among patients aged 75 yr compared with nonsurgical management [22].In the contemporary management of patients with localized RCC, other treatment options, such as active surveillance and ablative therapies, may also represent viable strategies. Nonetheless, it is noteworthy that in localized RCC, progression to metastatic disease is non-negligible (1 10%); the median survival time is approximately 21 mo [23,24]. Consequently, despite the potential roles of ablative therapies and active surveillance for small renal masses, further prospective studies with larger sample sizes and longer follow-up (5 yr) are needed. In summary, the treatment objectives for small renal masses extend well beyond tumor control. One has to consider not only the biology of the disease but also the effect of the treatment on non cancer-related survival. However, the selection of surgical candidates cannot be solely based on age and comorbidities; it must include other factors as recommended by the comprehensive geriatric society [25]. If active treatment is considered for localized RCC, the preservation of renal function should remain among the primary targets. That being said, while the findings of the current study are in line with previous population-based reports, a recent randomized controlled trial comparing PN and RN (n = 541) reported no difference with respect to overall survival (HR: 1.50; 95% CI, ; p = 0.8) [17]. Furthermore, RN conferred a longer survival compared with PN ( p = 0.03). The discrepancy between the findings of the randomized trial and the current report may stem from the inherent selection biases applicable to retrospective populationbased data, such as the SEER. It may be postulated that RN-treated patients in the current study were sicker and older at baseline, harbored more aggressive tumors, or both. Despite the attempt to reduce to a minimum the differences between PN and RN patients, propensity-based analysis cannot adjust for differences that are not available within the database. Previous analyses using retrospective observational data were also limited by this factor [6,7]. Nonetheless, well-designed population-based analyses are more generalizable and allow researchers and physicians to extend the results in this case, efficacy of treatment type in the large community. As such, while the current results may be different from those reported by Van Poppel et al. [17], they remain of essential importance. Finally, it is not surprising that baseline comorbid conditions were associated with an increased risk of OCM, which is a finding that is consistent with previous reports [26]. However, it is noteworthy that in the current study, hyperlipidemia was strongly associated with a protective effect on OCM (HR: 0.73, p = 0.003). A previous study examining survival among Medicare patients diagnosed with RCC also showed a similar effect (HR: 0.78, p < 0.001) [12]. It is possible that hyperlipidemia represents a marker condition that prompts closer follow-up and encourages physicians and patients to consider a broad range of health-promoting steps. These steps usually include dietary modalities and lifestyle changes that attempt to reduce weight, stress, and other detrimental effects. Conversely, exercise, relaxation, and use of pharmacologic agents such as statins [27] may further potentiate the effects of other measures. The net benefit likely relates to longer overall survival. Given the limitations of the SEER Medicare data, as well as the retrospective nature of the report, we may only speculate on the recorded observations. Although the reasons for these correlations remain unclear, additional studies using clinical data should investigate the influence of comorbidities on postoperative outcomes in RCC. Other limitations of the current study include restriction of the study sample to Medicare beneficiaries, which captures patients aged 65 yr only. This restriction may have compromised the generalizability of the results and may represent a major difference relative to previous studies that did not have an age restriction applicable to their analyses. Nonetheless, the current limitation may also be seen as a strength of the study, since elderly patients are often underrepresented in clinical trials. The lack of central pathology also represents a limitation. Furthermore, CCI was coded using administrative codes. While the validity of this method has been previously examined and properly established, the method may be associated with a degree of incorrectness [28]. Consequently, the distribution of comorbidities may not have been properly captured, which resulted in an improper consideration of baseline comorbidities and treatment type. The same observation may have also been operational for attribution of cause of death; some authors have voiced concerns about the reliability of death certificates in ascertainment of cause-of-death information. Specifically, several reports have demonstrated that attribution of cause of death is related to knowledge of previous treatment of prostate cancer [29]. While this effect may not have been directly operational in the current study, it remains a possible bias. Nonetheless, previous authors have examined the reliability of the coding and
6 730 EUROPEAN UROLOGY 61 (2012) reported a high degree of accuracy for cause of death within the SEER [30]. Finally, the lack of information on baseline kidney functions and serum creatinine levels to identify patients with preexisting and treatment-induced chronic kidney disease may have influenced the rates of OCM events. As such, the observed effect between treatment type and OCM cannot be inferred as a direct causal relationship but only as a mere correlation, which would need to be confirmed in future studies. 5. Conclusions Compared with PN-treated patients, RN-treated patients are more likely to die of OCM after surgery, even after adjusting for CSM, as well as baseline CCI. Consequently, PN should be offered whenever technically feasible. Author contributions: Maxine Sun had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Sun, Trinh, Bianchi, Hansen, Hanna, Karakiewicz. Acquisition of data: Sun, Karakiewicz. Analysis and interpretation of data: Sun, Bianchi. Drafting of the manuscript: Sun, Karakiewicz. Critical revision of the manuscript for important intellectual content: Trinh, Abdollah, Shariat, Briganti. Statistical analysis: Sun. Obtaining funding: Montorsi, Perrotte, Karakiewicz. Administrative, technical, or material support: Karakiewicz. Supervision: Montorsi, Perrotte, Karakiewicz. Other (specify): None. Financial disclosures: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Pierre I. Karakiewicz is partially supported by the University of Montreal Health Centre Urology Specialists, Fonds de la Recherche en Santé du Québec, the University of Montreal Department of Surgery andthe University of Montreal Health Centre (CHUM) Foundation. Funding/Support and role of the sponsor: None. References [1] Doeuk N, Guo D, Haddad R, et al. Renal cell carcinoma: stage, grade and histology migration over the last 15 years in a large Australian surgical series. BJU Int 2010;107: [2] Sun M, Thuret R, Abdollah F, et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 2011;59: [3] Baillargeon-Gagné S, Jeldres C, Lughezzani G, et al. A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma. BJU Int 2010;105: [4] Zini L, Patard JJ, Capitanio U, et al. The use of partial nephrectomy in European tertiary care centers. Eur J Surg Oncol 2009;35: [5] Weight CJ, Larson BT, Fergany AF, et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized ct1b renal masses. J Urol 2010;183: [6] Huang WC, Elkin EB, Levey AS, et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors is there a difference in mortality and cardiovascular outcomes? J Urol 2009;181:55 61, discussion [7] Zini L, Perrotte P, Capitanio U, et al. Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 2009;115: [8] Dulabon LM, Lowrance WT, Russo P, et al. Trends in renal tumor surgery delivery within the United States. Cancer 2010;116: [9] Warren J, Klabunde C, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(Suppl 8):3 18. [10] Klabunde C, Potosky A, Legler J, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53: [11] Charlson M, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40: [12] Hollenbeak C, Mallik R, Lehman E, et al. Treatment and survival among Medicare patients with renal cell carcinoma. Kidney Cancer J 2010;8: [13] Du XL, Fang S, Coker AL, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer 2006;106: [14] D Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statist Med 1998;17: [15] Stukel TA, Fisher ES, Wennberg DE, et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007;297: [16] Van Poppel H, Becker F, Cadeddu JA, et al. Treatment of localised renal cell carcinoma. Eur Urol 2011;60: [17] Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011; 59: [18] Kates M, Badalato GM, Pitman M, et al. Increased risk of overall and cardiovascular mortality after radical nephrectomy for renal cell carcinoma 2 cm or less. J Urol 2011;186: [19] Kim SP, Shah ND, Weight CJ, et al. Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort. J Urol 2011;186: [20] Sun M, Bianchi M, Trinh Q, et al. Hospital volume is a determinant of postoperative complication, blood transfusion, length of stay after radical or partial nephrectomy. J Urol 2012;187: [21] Miller DC, Wei JT, Dunn RL, et al. Trends in the diffusion of laparoscopic nephrectomy. JAMA 2006;295: [22] Lane BR, Abouassaly R, Gao T, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 2010;116: [23] Eggener SE, Yossepowitch O, Pettus JA, et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006;24: [24] Chawla SN, Crispen PL, Hanlon AL, et al. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 2006;175: [25] National Comprehensive Cancer Network. Senior adult oncology v [26] Lughezzani G, Sun M, Budäus L, et al. Population-based external validation of a competing-risks nomogram for patients with localized renal cell carcinoma. J Clin Oncol 2010;28:e
7 EUROPEAN UROLOGY 61 (2012) [27] Go A, Lee W, Yang JC, et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006;296: [28] Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53: [29] Newschaffer CJ, Otani K, McDonald K, et al. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 2000;92: [30] Penson DF, Albertsen PC, Nelson PS, et al. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst 2001;93:
EUROPEAN UROLOGY 60 (2011)
EUROPEAN UROLOGY 60 (2011) 920 930 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Monique J. Roobol and Eveline A.M. Heijnsdijk
More informationIndications For Partial
Indications For Partial Nephrectomy Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Endowed Professorship in Urology Department of Urology The University of Texas
More informationEUROPEAN UROLOGY 57 (2010)
EUROPEAN UROLOGY 57 (2010) 956 962 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Urothelial Cancer Editorial by Alexandre R. Zlotta on pp. 970 972 of this
More informationOptimal Treatment of ct1b Renal Mass in Patient with Normal GFR: a Role for Radical Nephrectomy?
Optimal Treatment of ct1b Renal Mass in Patient with Normal GFR: a Role for Radical Nephrectomy? Steven C. Campbell, MD, PhD Program Director, Vice Chairman Department of Urology Center for Urologic Oncology
More informationPartial Nephrectomy Is Associated with Improved Overall Survival Compared to Radical Nephrectomy in Patients with Unanticipated Benign Renal Tumours
EUROPEAN UROLOGY 58 (2010) 293 298 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Partial Nephrectomy Is Associated with Improved Overall Survival Compared to
More informationRobot-assisted vs. Laparoscopic Partial Nephrectomy: utilization rates and perioperative outcomes
ORIGINAL Article Vol. 39 (3): 377-386, May - June, 2013 doi: 10.1590/S1677-5538.IBJU.2013.03.11 Robot-assisted vs. Laparoscopic Partial Nephrectomy: utilization rates and perioperative outcomes Jesse D.
More informationWho are Candidates for Laparoscopic or Open Radical Nephrectomy. Arieh Shalhav
Who are Candidates for Laparoscopic or Open Radical Nephrectomy Arieh Shalhav Fritz Duda Chair of Urologic Surgery Professor of Surgery and the Comprehensive Cancer Research Center Who are Candidates for
More informationOverall Survival and Development of Stage IV Chronic Kidney Disease in Patients Undergoing Partial and Radical Nephrectomy for Benign Renal Tumors
EUROPEAN UROLOGY 64 (2013) 600 606 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Alexander Kutikov, Marc C. Smaldone and Robert
More informationOriginal Article - Urological Oncology
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.7.446 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.7.446&domain=pdf&date_stamp=2014-07-16
More informationOriginal Paper. Urol Int 2017;98:40 48 DOI: /
Urologia Internationalis Original Paper Urol Int 17;98: 48 DOI: 1.1159/447495 Received: March 29, 16 Accepted after revision: June 6, 16 Published online: August 4, 16 Differences in Patient Characteristics
More informationRAPN. in T1b Renal Masses? A. Mottrie. G. Denaeyer, P. Schatteman, G. Novara
RAPN in T1b Renal Masses? A. Mottrie G. Denaeyer, P. Schatteman, G. Novara Department of Urology O.L.V. Clinic Aalst OLV Vattikuti Robotic Surgery Institute Aalst Belgium Guidelines on Renal Cell Carcinoma
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationKey Words: kidney; carcinoma, renal cell; renal insufficiency; nephrectomy; mortality
Comparative Effectiveness for Survival and Renal Function of Partial and Radical Nephrectomy for Localized Renal Tumors: A Systematic Review and Meta-Analysis Simon P. Kim, R. Houston Thompson, Stephen
More informationELECTIVE PARTIAL NEPHRECTOMY FOR T1B RCC. Vitaly Margulis MD. Associate Professor of Urology
ELECTIVE PARTIAL NEPHRECTOMY FOR T1B RCC Vitaly Margulis MD Associate Professor of Urology NEPHRON SPARING SURGERY WHY? MAXIMIZING NEPHRON MASS SAVES LIVES ELECTIVE PARTIAL NEPHRECTOMY IF: TECHNICALLY
More informationTumor Grade Improves the Prognostic Ability of American Joint Committee on Cancer Stage in Patients With Penile Carcinoma
Tumor Grade Improves the Prognostic Ability of American Joint Committee on Cancer Stage in Patients With Penile Carcinoma Rodolphe Thuret,* Maxine Sun,* Firas Abdollah, Lars Budaus, Giovanni Lughezzani,
More informationORIGINAL INVESTIGATION. Effect of a Dementia Diagnosis on Survival of Older Patients After a Diagnosis of Breast, Colon, or Prostate Cancer
ORIGINAL INVESTIGATION Effect of a Dementia Diagnosis on Survival of Older Patients After a Diagnosis of Breast, Colon, or Prostate Cancer Implications for Cancer Care Mukaila A. Raji, MD, MSc; Yong-Fang
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationSt. Dominic s Annual Cancer Report Outcomes
St. Dominic s 2017 Annual Cancer Report Outcomes Cancer Program Practice Profile Reports (CP3R) St. Dominic s Cancer Committee monitors and ensures that patients treated at St. Dominic Hospital receive
More informationSurgical Management of Renal Cancer. David Nicol Consultant Urologist
Surgical Management of Renal Cancer David Nicol Consultant Urologist Roles of Surgery 1. Curative intervention localised disease 2. Symptomatic control advanced disease 3. Augmentation of efficacy of systemic
More informationComparison of Glomerular Filtration Rate (GFR) (RCC)
Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X) Vol. 3(10) pp. 467-471, October, 2015 Available online http://www.meritresearchjournals.org/mms/index.htm Copyright 2015 Merit
More informationConclusions. Keywords
The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study Giorgio Gandaglia*, Maxine Sun*, Ioana
More informationEUROPEAN UROLOGY 61 (2012)
EUROPEAN UROLOGY 61 (2012) 480 487 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by A. Heidenreich on pp. 488 490 of this issue
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationProstate Cancer and Prostatic Disease (2014), Macmillan Publishers Limited All rights reserved /14
Prostate Cancer and Prostatic Disease (2014), 1 7 2014 Macmillan Publishers Limited All rights reserved 1365-7852/14 www.nature.com/pcan ORIGINAL ARTICLE Predicting prostate cancer-specific outcome after
More informationIs There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented by the Revised 7th TNM Version?
EUROPEAN UROLOGY 59 (2011) 258 263 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Is There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented
More informationTreatment disparities for patients diagnosed with metastatic bladder cancer in California
Treatment disparities for patients diagnosed with metastatic bladder cancer in California Rosemary D. Cress, Dr. PH, Amy Klapheke, MPH Public Health Institute Cancer Registry of Greater California Introduction
More informationLymphadenectomy in RCC: Yes, No, Clinical Trial?
Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University
More informationCanadian Guidelines for Management of the Small Renal Mass (SRM)
Canadian Guidelines for Management of the Small Renal Mass (SRM) Michael A.S. Jewett*, Ricardo Rendon, Louis Lacombe, Pierre I. Karakiewicz, Simon Tanguay, Wes Kassouf, Mike Leveridge, Ilias Cagiannos,
More informationWhen to perform preoperative chest computed tomography for renal cancer staging
When to perform preoperative chest computed tomography for renal cancer staging Alessandro Larcher*, Paolo Dell Oglio*, Nicola Fossati*, Alessandro Nini*, Fabio Muttin*, Nazareno Suardi*, Francesco De
More informationTable 1. Descriptive characteristics, total prostate-specific antigen, and percentage of free/total prostate-specific antigen distribution Age Groups
Oncology Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort Umberto Capitanio, Paul Perrotte, Laurent Zini, Nazareno Suardi, Elie Antebi,
More informationDebate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.
Debate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.. Eighth European International Kidney Cancer Symposium Budapest 03-04 May 2013 The role of LND In organ confined
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationCarcinoma renale (I): Posters Review. Elena Verzoni Oncologia Medica 1 SS.Oncologia Genitourinaria Fondazione IRCCS Istituto Nazionale Tumori Milano
Carcinoma renale (I): Posters Review Elena Verzoni Oncologia Medica 1 SS.Oncologia Genitourinaria Fondazione IRCCS Istituto Nazionale Tumori Milano Agenda: Best Posters in Localized RCC Surgery: CN (#
More informationTHE INCIDENCE OF KIDNEY CANcer
ORIGINAL CONTRIBUTION Long-term Survival Following Partial vs Radical Nephrectomy Among Older Patients With Early-Stage Kidney Cancer Hung-Jui Tan, MD Edward C. Norton, PhD Zaojun Ye, MS Khaled S. Hafez,
More informationPartial versus radical nephrectomy for pt1a renal cancer in Serbia
JBUON 2016; 21(6): 1449-1453 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Partial versus radical nephrectomy for pt1a renal cancer in Serbia
More informationThe Linked SEER-Medicare Data and Cancer Effectiveness Research
The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 2 JANUARY 0 200 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Evaluating Overall Survival and Competing Risks of Death in Patients With Localized Renal Cell Carcinoma Using
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 24 AUGUST 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T A Nomogram Predicting 10-Year Life Expectancy in Candidates for Radical Prostatectomy or Radiotherapy for Prostate
More informationComparison of radiographic and pathologic sizes of renal tumors
ORIGINAL Article Vol. 39 (2): 189-194, March - April, 2013 doi: 10.1590/S1677-5538.IBJU.2013.02.06 Comparison of radiographic and pathologic sizes of renal tumors Wei Chen, Linhui Wang, Qing Yang, Bing
More informationWhat is the role of partial nephrectomy in the context of active surveillance and renal ablation?
What is the role of partial nephrectomy in the context of active surveillance and renal ablation? Dogu Teber Department of Urology University Hospital Heidelberg Coming from Heidelberg obligates to speak
More informationState-of-the-art: vision on the future. Urology
State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures
More informationDAYS IN PANCREATIC CANCER
HOSPITAL AND MEDICAL CARE DAYS IN PANCREATIC CANCER Annals of Surgical Oncology, March 27, 2012 Casey B. Duncan, Kristin M. Sheffield, Daniel W. Branch, Yimei Han, Yong-Fang g Kuo, James S. Goodwin, Taylor
More informationThe American Cancer Society estimates that there will be
ORIGINAL ARTICLE Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,* David M. Kent, MD, MS, and Gary M.
More informationWHAT IS THE ROLE OF ACTIVE SURVEILLANCE
WHAT IS THE ROLE OF ACTIVE SURVEILLANCE IN THE CONTEXT OF RENAL ABLATION AND PARTIAL NEPHRECTOMY? Alessandro Volpe University of Eastern Piedmont Novara, Italy RCC INCIDENCE SEER DATABASE (1975-2006) RCC
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationAdjuvant Chemotherapy for Patients with Stage III Colon Cancer: Results from a CDC-NPCR Patterns of Care Study
COLON CANCER ORIGINAL RESEARCH Adjuvant Chemotherapy for Patients with Stage III Colon Cancer: Results from a CDC-NPCR Patterns of Care Study Rosemary D. Cress 1, Susan A. Sabatino 2, Xiao-Cheng Wu 3,
More informationPatient and Hospital Characteristics Associated with Nephron-Sparing Surgery for Small, Localized Kidney Cancers in California,
Patient and Hospital Characteristics Associated with Nephron-Sparing Surgery for Small, Localized Kidney Cancers in California, 2012-2015 Brenda M. Giddings, M.A. California Cancer Reporting and Epidemiologic
More informationEUROPEAN UROLOGY 62 (2012)
EUROPEAN UROLOGY 62 (2012) 472 487 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Judd W. Moul on pp. 488 490 of this issue
More informationRacial Disparities and Socioeconomic Status in Men Diagnosed With Testicular Germ Cell Tumors
Racial Disparities and Socioeconomic Status in Men Diagnosed With Testicular Germ Cell Tumors A Survival Analysis Maxine Sun, BSc 1 ; Firas Abdollah, MD 1,2 ; Daniel Liberman, MD 1,3 ; Al a Abdo, MD 1,3
More informationBLACK-WHITE DIFFERENCES IN SURVIVAL FROM LATE-STAGE PROSTATE CANCER
BLACK-WHITE DIFFERENCES IN SURVIVAL FROM LATE-STAGE PROSTATE CANCER Objective: To examine differences between African Americans (Blacks) and non-hispanic Whites in risk of death after diagnosis of laterstage
More informationThe Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer
Original Research 1351 The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer Nicola Fossati, MD a,b ; Daniel P. Nguyen, MD c ; Quoc-Dien
More informationEUROPEAN UROLOGY 62 (2012)
EUROPEAN UROLOGY 62 (2012) 745 752 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Allison S. Glass, Matthew R. Cooperberg and
More informationEUROPEAN UROLOGY 61 (2012)
EUROPEAN UROLOGY 61 (2012) 1156 1161 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Alvin C. Goh and Inderbir S. Gill on pp. 1162
More informationAnalysis of the outcome of young age tongue squamous cell carcinoma
Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of
More informationSegmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer
Int Urol Nephrol (2014) 46:921 926 DOI 10.1007/s11255-013-0514-z UROLOGY - ORIGINAL PAPER Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter
More informationTHE IMPORTANCE OF COMORBIDITY TO CANCER CARE AND STATISTICS AMERICAN CANCER SOCIETY PRESENTATION COPYRIGHT NOTICE
THE IMPORTANCE OF COMORBIDITY TO CANCER CARE AND STATISTICS AMERICAN CANCER SOCIETY PRESENTATION COPYRIGHT NOTICE Washington University grants permission to use and reproduce the The Importance of Comorbidity
More informationTHE SURVIVAL BENEFITS OF
ORIGINAL INVESTIGATION Adjuvant Chemotherapy After Resection in Elderly Medicare and Medicaid Patients With Colon Cancer Cathy J. Bradley, PhD; Charles W. Given, PhD; Bassam Dahman, MS; Timothy L. Fitzgerald,
More informationContemporary Role of Renal Mass Biopsy
Contemporary Role of Renal Mass Biopsy Jeffrey K. Mullins, MD Director Urologic Oncology CHI Memorial Chattanooga Urology Associates September 8, 2018 Disclosures I, Jeffrey Mullins, do not have a financial
More informationAnatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score
EUROPEAN UROLOGY 60 (2011) 241 248 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Brian F. Chapin and Christopher G. Wood on pp.
More informationFactors Associated with Initial Treatment for Clinically Localized Prostate Cancer
Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Preliminary Results from the National Program of Cancer Registries Patterns of Care Study (PoC1) NAACCR Annual Meeting
More informationHospitalization Costs for Radical Prostatectomy Attributable to Robotic Surgery
EUROPEAN UROLOGY 64 (2013) 11 16 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Yair Lotan on pp. 17 18 of this issue Hospitalization
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationRenal Tumor Contact Surface Area: A Novel Parameter for Predicting Complexity and Outcomes of Partial Nephrectomy
EUROPEAN UROLOGY 66 (2014) 884 893 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Homayoun Zargar, Riccardo Autorino, Oktay Akca
More informationTHE SURVIVORSHIP EXPERIENCE IN PANCREATIC CANCER
THE SURVIVORSHIP EXPERIENCE IN PANCREATIC CANCER Casey A. Boyd, Jaime Benarroch, Kristin M. Sheffield, Yimei Han, Catherine D. Cooksley, Taylor S. Riall Department of Surgery The University of Texas Medical
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationChallenges in RCC surgery. Treatment Goals. Surgical challenges. Management options in VHL associated RCCs
Management options in VHL associated RCCs Challenges in RCC surgery JJ PATARD, MD, PhD Paris XI University Observation, Radical nephrectomy, Renal parenchymal sparing surgery, Open, laparoscopic, robotic
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
A Contemporary, Population-Based Analysis of the Incidence, Cost, Outcomes, and Preoperative Risk Prediction of Postoperative Delirium Following Major Urologic Cancer Surgeries The Harvard community has
More informationRobotic Partial Nephrectomy Versus Laparoscopic Cryoablation for the Small Renal Mass
EUROPEAN UROLOGY 61 (2012) 899 904 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Jose A. Karam and Christopher G. Wood on pp.
More informationPatient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.
Patient Selection for Surgery in RCC with Thrombus E. Jason Abel, M.D. RCC with venous invasion Venous invasion occurs in ~10% of RCC Surgery more complex Increased risk for morbidity Thrombus may be confined
More informationS.C.D.U. Urologia Dir.: prof. Francesco Porpiglia
UNIVERSITA degli STUDI di TORINO Facolta di Medicina e Chirurgia, Polo San Luigi Dipartimento di Oncologia S.C.D.U. Urologia Dir.: prof. Francesco Porpiglia A.O.U. San Luigi Gonzaga Orbassano Chirurgia:
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1428 1437 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Platelet Count and Preoperative Haemoglobin Do Not Significantly Increase
More informationhad non-continuous enrolment in Medicare Part A or Part B during the year following initial admission;
Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries Weiss J P, Saynina O, McDonald K M, McClellan M
More informationIncidence and Determinants of 1-Month Mortality after Cancer-Directed Surgery
Annals of Oncology Advance Access published November 27, 2014 1 Incidence and Determinants of 1-Month Mortality after Cancer-Directed Surgery B.A. Mahal 1,*, G. Inverso 2,*, A.A. Aizer 3, D.R. Ziehr 1,
More informationSatisfaction and Regret after Open Retropubic or Robot- Assisted Laparoscopic Radical Prostatectomy
european urology 54 (2008) 785 793 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Satisfaction and Regret after Open Retropubic or Robot- Assisted Laparoscopic
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationUse of Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer in the United States
International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation: Thoracic Cancer Use of Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer
More informationPrediction of complications after partial nephrectomy by RENAL nephrometry score
UROLOGY Ann R Coll Surg Engl 04; 96: 475 479 doi 0.308/00358844X3946849035 Prediction of complications after partial nephrectomy by RENAL nephrometry score UD Reddy, R Pillai, RA Parker, J Weston, NA Burgess,
More informationBJUI. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy
BJUI Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy Nilay Patel, David Cranston, M. Zeeshan Akhtar, Caroline George, Andrew
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationRisk of renal side effects with ADT. E. David Crawford University of Colorado, Aurora, CO, USA
Risk of renal side effects with ADT E. David Crawford University of Colorado, Aurora, CO, USA ADT: A key treatment for advanced prostate cancer John Hunter 1780-castration 1904: First RP 1938: Acid Phos.
More informationA DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY. Helen Mari Parsons
A Culture of Quality? Lymph Node Evaluation for Colon Cancer Care A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Helen Mari Parsons IN PARTIAL FULFILLMENT
More informationStaging Laparoscopy in the Management of Gastric Cancer: A Population-Based Analysis
Staging Laparoscopy in the Management of Gastric Cancer: A Population-Based Analysis Paul J Karanicolas, MD, PhD, Elena B Elkin, PhD, Lindsay M Jacks, MSc, Coral L Atoria, MPH, Vivian E Strong, MD, FACS,
More informationAdverse Renal Outcomes in Subjects Undergoing Nephrectomy for Renal Tumors: A Population-Based Analysis
EUROPEAN UROLOGY 59 (2011) 333 339 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Paul Russo on pp. 340 341 of this issue Adverse
More informationA Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy
1254 A Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy Nazareno Suardi, MD 1,2 Christopher R. Porter, MD 3 Alwyn M. Reuther, MD 4 Jochen Walz, MD 1,5 Koichi Kodama, MD
More informationProspective multi-center study of oncologic outcomes of robot-assisted partial nephrectomy for pt1 renal cell carcinoma
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2012 Prospective multi-center study of oncologic outcomes of robot-assisted partial nephrectomy for pt1 renal cell
More informationAccepted for publication 3 January 2005
Original Article RACIAL DIFFERENCES IN PSA DOUBLING TIME AND RECURRENCE TEWARI et al. In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several
More informationTrends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma
Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Taylor S. Riall, MD, PhD CERCIT Workshop October 19, 2012 Department of Surgery Center for Comparative Effectiveness
More informationSurgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 23 March 2012, Sao Paulo, Brazil Surgery of RCC Locally confined (small) renal tumours Locally advanced disease Metastatic
More informationClinical Stage Migration and Survival for Renal Cell Carcinoma in the United States
ava ilable at www.sciencedirect.com journa l homepage: euoncology.europeanurology.com Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States Hiten D. Patel *, Mohit Gupta,
More informationComparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments
Comparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments Prepared for: American Hospital Association April 4, 2019 Berna Demiralp,
More informationBeyond biology: the impact of marital status on survival of patients with adrenocortical carcinoma
ORIGINAL ARTICLE Vol. 41 (6): 1108-1115, November. December, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0348 Beyond biology: the impact of marital status on survival of patients with adrenocortical carcinoma
More informationDistribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer
Urological Oncology CHUN et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer Felix K.-H. Chun, Georg C.
More informationVincenzo Ficarra 1,2,3. Associate Editor BJU International
Partial Nephrectomy for RCC Vincenzo Ficarra 1,2,3 1 Director Department of Urology University of Udine, Italy 2 Associate Editor BJU International 3 Scientific Director OLV Robotic Surgery Institute,
More informationLymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
More informationReimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer
Shahinian and Kuo BMC Urology (2015) 15:25 DOI 10.1186/s12894-015-0020-y RESEARCH ARTICLE Open Access Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer
More informationRates and patterns of participation in cardiac rehabilitation in Victoria
Rates and patterns of participation in cardiac rehabilitation in Victoria Vijaya Sundararajan, MD, MPH, Stephen Begg, MS, Michael Ackland, MBBS, MPH, FAPHM, Ric Marshall, PhD Victorian Department of Human
More informationZonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy
european urology 51 (2007) 949 955 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical
More information